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Advances in closed-loop deep brain
stimulation devices
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Abstract
Background: Millions of patients around the world are affected by neurological and psychiatric disorders. Deep
brain stimulation (DBS) is a device-based therapy that could have fewer side-effects and higher efficiencies in
drug-resistant patients compared to other therapeutic options such as pharmacological approaches. Thus far,
several efforts have been made to incorporate a feedback loop into DBS devices to make them operate in a
closed-loop manner.
Methods: This paper presents a comprehensive investigation into the existing research-based and commercial
closed-loop DBS devices. It describes a brief history of closed-loop DBS techniques, biomarkers and algorithms
used for closing the feedback loop, components of the current research-based and commercial closed-loop
DBS devices, and advancements and challenges in this field of research. This review also includes a
comparison of the closed-loop DBS devices and provides the future directions of this area of research.
Results: Although we are in the early stages of the closed-loop DBS approach, there have been fruitful efforts in
design and development of closed-loop DBS devices. To date, only one commercial closed-loop DBS device
has been manufactured. However, this system does not have an intelligent and patient dependent control
algorithm. A closed-loop DBS device requires a control algorithm to learn and optimize the stimulation
parameters according to the brain clinical state.
Conclusions: The promising clinical effects of open-loop DBS have been demonstrated, indicating DBS as a
pioneer technology and treatment option to serve neurological patients. However, like other commercial
devices, DBS needs to be automated and modernized.
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Background
Deep Brain Stimulation (DBS) can be classified into
open-loop (also known as conventional) and closed-loop
(also known as adaptive) paradigms. Closed-loop DBS
employs a sensor to record a signal linked to symptoms
while open-loop DBS does not use a sensor for record-
ing the brain condition; therefore, stimulation parame-
ters including duration, amplitude, and frequency of the
pulse train remain constant in open-loop DBS regardless
of fluctuations in the disease state. The recorded signal
is known as a biomarker and can have varying nature,
e.g. bioelectric, physiologic, biochemical, etc. In the
open-loop DBS, a specialist tracks the patient’s clinical
state and manually programs the device in a trial-and-
error based manner. Adjustments of stimulation param-
eters are not conducted in real-time based on the on-
going neurophysiological variations in the brain;
therefore, adverse effects on the patient may be induced
due to the brain overstimulation. On the other hand, in
the closed-loop DBS, the stimulation pulses are delivered
when the brain is in an abnormal state, or they are
automatically and dynamically adjusted based on the
variations in the recorded signal over the time. Figure 1
compares open-loop and closed-loop DBS and illustrates
how they act in different brain states.
Although the conventional DBS is a successful ther-
apy, the closed-loop DBS is potentially capable of further
and more efficient improvements in neurological
diseases. A systematic review of the clinical literature by
Hamani et al. [1] stated that adjusting the stimulation* Correspondence: mparasta@deakin.edu.au
School of Engineering, Deakin University, Waurn Ponds, VIC 3216, Australia
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Parastarfeizabadi and Kouzani Journal of NeuroEngineering and Rehabilitation  (2017) 14:79 
DOI 10.1186/s12984-017-0295-1
parameters of DBS devices could reduce or abolish ad-
verse effects reported in 142 (19%) of 737 Parkinson’s
disease (PD) patients treated with subthalamic nucleus
(STN) DBS. In addition, Rosin et al. [2] demonstrated
the superior function of closed-loop DBS, which auto-
matically adjusts the stimulation parameters, to alleviate
PD symptoms. Moreover, Little et al. [3] indicated that
motor scores in eight PD patients improved by 50%
(blinded) and 66% (unblinded) during closed-loop DBS,
which were 27% (p = 0.005) to 29% (p = 0.03) higher
than that of open-loop DBS. Besides these therapeutic
benefits, they reported 56% reduction in stimulation
time, as well as a decrease in the energy requirement of
the closed-loop DBS compared to open-loop DBS.
Therefore, patients may also benefit from fewer surgeries
for replacement of the neurostimulator battery as a re-
sult of less power consumption in non-continuous stim-
ulations [3]. Little et al. [3] and Wu et al. [4] reported
that in order to obtain similar results from open-loop
and closed-loop DBS, 44% less electrical stimulation is
required using closed-loop DBS, which means higher ef-
ficiency, fewer surgery numbers, lower power consump-
tion, and longer battery lifespan.
Although DBS is a successful therapy, its operation
mechanism is mainly uncertain. Hess et al. [5] explained
how the temporal pattern of stimulations might have
key information for clarification of the DBS mechanism.
A recent short review [6] on the physiological mechan-
ism of DBS suggests the “disruption hypothesis” in
which abnormal information is prevented from flowing
into the stimulation site as a result of DBS dissociation
effect on input and output signals. However, it is still
under debate and remains to be confirmed by more pre-
clinical research. Another review by Herrington et al. [7]
accounts several non-exclusive mechanisms for DBS that
depend on the condition being treated and the stimula-
tion target. Despite the existence of different theories on
the DBS mechanism, there are still questions in regard
to the closed-loop DBS. Does adaptive control of DBS
alter the DBS mechanism? If yes, how does it alter the
DBS mechanism? These questions deserve consideration
in the future experimental studies.
This paper presents a comprehensive review of portable
closed-loop DBS devices. While there exists a number of
excellent reviews on closed-loop DBS systems [8–16], this
work differs from the existing works as described in the fol-
lowing. Among the published reviews, ref. [8] mainly high-
lights the applications of closed-loop DBS in the
rehabilitation of movement disorders. Ref. [12] mainly de-
scribes the benefits of closed-loop DBS which using local
field potentials (LFPs) as the feedback biomarker. Ref. [13]
mainly reviews DBS (both open-loop and closed-loop) in
terms of neurological aspects and clinical benefits. Ref. [9]
indicates the available biomarkers for closing the feedback
loop, and gives control strategies for manipulating mea-
sured signals relating to PD patient clinical state. Ref. [10]
concentrates on emerging techniques in DBS including
new electrode design, new stimulation patterns, and novel
targeting techniques. Ref [16] has mainly focused on selec-
tion of biomarker and its benefits and problems. Ref. [14]
introduces adaptive DBS, and outlines some technological
advances in DBS including stimulation type and patterns,
energy harvesting, and methods for increasing life quality
of patients. Similarly, ref. [15] reviews some technological
Fig. 1 Overview of open-loop DBS (a) versus closed-loop DBS (b). In open-loop DBS, a neurologist manually adjusts the stimulation parameters
every 3–12 months after DBS implantation. On the other hand, in closed-loop DBS, programming of the stimulation parameters is performed
automatically based on the measured biomarker. c Demonstration of two different brain states and the action of open-loop and closed-loop DBS.
When the brain enters a specific state, it remains in that state for a short or long time. Closed-loop DBS gets deactivated when the brain enters
the normal state. Open-loop DBS continues the stimulation regardless of the brain state
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advancement such as surgical targeting, DBS parameters
programming, and electrode design. On the other hand,
ref. [11] highlights a range of issues associated with closed-
loop DBS including biomarker sensing and processing,
DBS parameters programming, control algorithm, wireless
telemetry, and device size and power consumption.
This paper, on the other hand, provides a comprehensive
review of closed-loop DBS devices, and covers a wider
range of issues and advancements associated with such de-
vices including: (i) biomarker selection, (ii) DBS parameters
programming, (iii) stimulation type and pattern, (iv) control
algorithms, (v) concurrent stimulation and recording, (vi)
portability, (vii) battery-less technique, (viii) user-friendly
interface, and (x) remote monitoring and wireless telemetry.
The paper combines the key features of the current reviews
going beyond devices that are used for specific disorders or
biomarkers. It covers closed-loop DBS devices reported in
the latest research publications not included in the existing
reviews. The paper gives a brief history of closed-loop DBS.
Next, it discusses different biomarkers for closing the feed-
back loop. Then, it reviews the algorithms developed for
controlling stimulation parameters. After that, it highlights
the current challenges and limitations for implementing
closed-loop DBS. Also, it reviews the technological develop-
ments in closed-loop DBS. Then, it describes commercial
closed-loop DBS systems. After that, it compares research-
based closed-loop DBS devices highlighting future design
expectations, and giving future directions and recommen-
dations on closed-loop DBS devices.
Brief history of closed-loop DBS
The review of scientific literature reveals that the initial
use of closed-loop against open-loop DBS goes back to
early 2000 [17] when an ultra-short-term closed-loop
neurostimulator device was introduced being capable of
stimulation by detection of seizures. This initial pilot
study led to optimistic findings which were confirmed
by other studies during 2002–2005. These studies
[18, 19] concentrated on an external responsive
neurostimulator (RNS) system capable of detecting
seizures, delivering stimulations in a semi-closed-
loop manner, and storing electrocorticogram (ECoG)
potentials. These studies had promising conse-
quences on seizure activity of 11 out of 27 patients.
However, due to the low specificity of seizure detec-
tion of the RNS [20], it was not entirely considered
as an adaptive DBS triggered by seizures [21].
Following the use of a semi-closed-loop DBS device on
epileptic patients, the idea of dynamically controlling DBS
became a target for many researchers. However, imple-
mentation of closed-loop DBS was postponed due to the
difficulties associated with technical and computational
aspects, and the reliability of selected biomarkers.
Selection of biomarkers and control algorithm for epilepsy
could be less complicated than that for other neurological
disorders (because of a distinguishable shape of the
seizures activities compared to the non-seizure neural
signal). Thus, lack of reliable biomarkers for most of
neurological disorders postponed the development of a
closed-loop DBS device for such disorders. Later, various
investigations were initiated to address the problems
associated with the use of closed-loop DBS for several
neurological disorders. These attempts have been
performed towards developments of closed-loop DBS
devices, which are discussed in detail in the later sections
of this review.
Biomarkers for closing of the feedback loop
It is crucial for a closed-loop DBS device to take advantage
of a feedback signal in the control loop to eliminate the
problems associated with open-loop adjustments of stimu-
lation parameters. Open-loop adjustment of stimulation
parameters is not an efficient procedure. In the past
decade, various physiological signals have been used as a
feedback in the closed-loop DBS systems. Action poten-
tials (APs) [2, 22], ECoGs [23, 24], LFPs [3, 12, 25–28],
and electroencephalogram (EEGs) [29] are examples of
electrophysiological biomarkers considered in the
feedback loop of adaptive DBS systems (see Fig. 2 for de-
tails on the layer of extraction). Aside from electrophysio-
logical signals, some researchers have focused on creating
the feedback loop using other biomarkers such as electro-
myogram (EMG) [30–33], and biochemical [34] signals. In
addition, Hebb et al. proposed the optical and mechanical
signals as other possible control signals [9]. However,
these signals require further assessments in terms of their
practicality. Each biomarker comprises merits and
demerits concerning invasiveness, signal content, and
resolution, as well as suitability for a disorder type [9] (see
Table 1).
The cortical EEG in PD patients have shown relevance
to abnormal basal ganglia circuit functions [29]. In
addition, high thalamocortical theta coherence has been
verified in PD patients [35]. These features indicate that
the cortical EEG signal could be used as a relevant
biomarker to the PD symptoms, especially because of its
non-invasive nature. However, it suffers from low
amplitude (maximum 10–20 μv [36]), low spatial
resolution (~3–9 cm [37, 38]), high noise and artifacts
sensitivity (e.g. to eye movements [39]), as well as lack of
high-frequency components (typically between
0.5–40 Hz [36]). These limitations mainly arise from
longer distance of the sensing electrode from the neur-
onal potential sources. In addition to the stated limita-
tions, the patient’s freedom of movement is restricted
through the non-implantable electrodes. Therefore, it
causes discomfort to the patient due to the attachment
of electrodes to the head.
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ECoG as another biomarker has been used by Afshar et
al. study [23]. They proposed an ECoG-based brain-
machine interface system and presented a correlation of
ECoG with the disease state. In comparison with EEG,
ECoG has higher signal quality in both amplitude and fre-
quency ranges (maximum 50–100 μv with frequencies be-
tween 0.5–500 Hz [36]). This feature has made ECoG a
signal with higher popularity in neuroscience research, es-
pecially for brain-computer interface (BCI) applications.
However, selecting ECoG as a biomarker requires place-
ment of subdural electrodes in the brain epidural or sub-
dural spaces, which are still away from the neuronal
stimulation site. Thus, the concerns on the spatial reso-
lution of ECoG signals may still exist. For instance, the
spatial resolution deteriorates significantly from 1.25 mm to
1.4 mm by placing the electrode on the epidural instead of
subdural space [40, 41]. Moreover, the difference in the re-
cording and stimulation electrodes may yield additional
costs and longer implantation and anesthesia duration that
may impose further brain injuries.
In contrast, APs, because of their high spatial resolution
(maximum 0.2 mm [38]), can be a good candidate as a
biomarker for controlling adaptive DBS devices. Typical
APs recorded extracellularly have an amplitude of up to
500 μV (100 mV intracellularly [42]) with frequencies be-
tween 100 Hz - 7 kHz [43]. However, continuous recording
of APs can cause death of neurons (if intracellular).
Moreover, there is a need for recalibration processes to
keep the stability of feedback signal [44]. Thus, these limita-
tions prevent the use of APs as a biomarker for long-term
stimulation. Furthermore, other biomarkers such as
biochemical potentials need stabilization of the carbon fiber
microelectrode during recording [45]. Furthermore,
applying other biomarkers such as EMG seem to have simi-
lar limitations as EEG. Moreover, EMG is linked to only a
limited number of diseases including PD and essential
tremor [30–33].
On the other hand, LFPs are the most used feedback
signal in closed-loop DBS [3, 12, 26]. LFPs, also known
as intracranial EEG [46], are potentials generated in the
extracellular space by propagation of APs through axons.
These local potentials reflect neuronal processes
occurring within a local region around electrode in the
neuronal extracellular space [47]. Priori et al. review [12]
Fig. 2 a A schematic representing different brain layers and measurable electrophysiological signals. Recording from higher depths results in potentials
with higher strength and quality. The higher the distance of electrode from the potential source means a larger impedance. Therefore, proportional to the
distance, the potentials are attenuated and high-frequency components are rejected due to the low-pass filtering behavior of the brain layers [159, 160]. In
addition, recording from an electrode with smaller contact area enables measuring potentials from fewer neurons [161]. b Amplitude vs frequency
characteristics of the human brain potentials of interest. c The spatial resolution of electrophysiological signals. d Three-shell head model. Different layers of
the head, particularly the skull with a large resistivity, induce a distorting effect on the potentials that reach the scalp surface
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demonstrated the suitability of LFPs as the feedback sig-
nal in closed-loop DBS devices for PD patients. One key
advantage is that LFPs can be directly recorded from the
stimulation electrodes. Another advantage of LFPs is the
long-term stability achieved at the electrode-tissue inter-
face [48]. LFPs generally have amplitudes of up to
200 μV with energies below 500 Hz [49]. Compared to
APs, LFPs have a reasonable spatial resolution, typically
around 1 mm [38]. As discussed in a review by Deeb et
al. [50], thus far several neurological disorders have been
investigated with closed-loop DBS systems controlled by
LFPs. While PD and epilepsy have been mainly focused
on, other disorders including Tourette syndrome, major
depression, and tremor have been also tried recently.
Generally, the selection of a proper biomarker depends
on several factors. It is usually chosen with respect to
the disease type and the degree of relevance to the
disease symptoms. Apart from being linked to a symp-
tom, it is vital for a biomarker to be recorded with a
high signal to noise ratio, and most importantly be stable
and unaffected by external artifacts such as movement,
talking, and thinking [11].
Control of feedback and stimulation parameters
Automatic and non-subjective optimization of closed-
loop stimulation parameters can enhance the patients’
therapeutic benefits while minimizing the side effects.
Although the neurologists reprogram the open-loop
DBS to enhance the therapeutic results, the procedure is
not optimal and would not deliver the best therapeutic
effects [2]. Simultaneous and automatic control of
stimulation parameters could improve the effectiveness
of therapy. A schematic of the closed-loop DBS pro-
gramming process is illustrated in Fig. 3.
Several neurological diseases are caused by synchro-
nized populations of oscillatory neurons. In some pa-
tients, open-loop DBS may not yield desynchronization
or its therapeutic effect may decline over time [51]. In
particular, the brain reaction to a constant set of stimu-
lation parameters may change gradually over time due
to the external (environmental) or internal (disease pro-
gress, and behavioral) factors [52, 53]. This procedure is
called neural plasticity which is the ability of the nervous
system to adopt a new functional or structural state in
response to extrinsic and intrinsic factors [54].
During the past decades, several model-based closed-
loop stimulation methods have been developed in order to
restore desynchronized dynamics in networks of oscilla-
tory neurons. These methods include single-site linear
[55, 56], multi-site linear [57, 58], and non-linear [59–62]
delayed feedback stimulation techniques, which intrinsic-
ally operate in a closed-loop or demand-controlled man-
ners. Another model-based method for desynchronization
of oscillatory neurons was proposed by Tukhlina et al.
[63] which is an implementation of a phase shifter. In this
method, suppression of neural synchrony is realized by or-
ganizing an interaction between the ensemble and a pas-
sive oscillator [63]. In recent published works [64, 65],
Popovych et al. combined the closed-loop DBS approach
with desynchronizing stimulation protocols. They ex-
tended linear and non-linear delayed feedback stimulation
methods to a pulsatile closed-loop DBS, and showed ef-
fective and robust desynchronization of STN-GPe model
neurons. In addition, they showed that the presence of an
interphase gap between the recharging phases of the
charge-balanced biphasic pulses can significantly improve
the stimulation-induced desynchronization in a closed-
loop DBS. Here, the amplitude of the stimulation pulses
was adjusted by the LFP feedback signal based on linear
or nonlinear delayed feedback rules.
In addition to the above presented works, there exist
many other interesting reports on development of an
optimized controller for programming of stimulation
parameters. Santaniello et al. [66] developed a model-
based controller through simulation of intrinsically ac-
tive neurons in the Vim thalamus and getting LFPs from
the neurons. This controller works based on a recursive
autoregressive model and adjusts the stimulation ampli-
tude automatically based on the feedback signal
recorded from the stimulation electrodes. Pyragas et al.
[67] presented a demand-controlled method for
suppression of neural synchrony using a proportional-
integral-derivative (PID) feedback, which enables robust
restoration of desynchronized states. Similarly, Gorzelic
et al. [68] and Dunn et al. [69] suggested model-based
algorithms that operate based on PID feedback. Their
suggested algorithms enable optimization of stimulation pa-
rameters in the closed-loop DBS. In addition, an adaptive
feedback input-output linearization algorithm for closed-
loop control of PD has been proposed by Su et al. [70]. This
algorithm adjusts the input signal based on the estimation
of parameters from the feedback signal. Rhew et al. [25]
designed a log-based adaptive DBS device that utilizes low-
pass-filtered LFPs in a proportional-integral (PI) controller
to define the optimum stimulation amplitudes. This
system works based on biomarker energy and benefits
from a robust feedback controller because of remov-
ing high-frequency artifacts from the controller input.
Another interesting controller has been designed that
operates based on variations in the neurochemical re-
lease [34]. The integration of recording and stimula-
tion modules is facilitated via fast-scan cyclic
voltammetry (FSCV). This system records artifact-free
evoked neurochemical alterations to wirelessly control
the stimulation parameters [34]. Another neurochem-
ical controller is proposed by Grahn et al. [71] in
which evoked dopamine changes are recorded to
adapt the stimulation parameters in a rodent model.
Parastarfeizabadi and Kouzani Journal of NeuroEngineering and Rehabilitation  (2017) 14:79 Page 6 of 20
Some of these closed-loop controllers, however, only
control one of the pulse parameters (usually amplitude)
or just implement a simple ON-OFF control of stimula-
tions. The on-demand systems trigger the DBS switch to
act only when the stimulation is needed. It is a simplified
form of closed-loop DBS capable of preventing brain
over-stimulation. The idea is to set a threshold and
check the biomarker continually, finding when it crosses
the threshold to turn on or off the stimulations. This
type of strategy to control the stimulation pulses in a
closed-loop DBS is based on an “amplitude-responsive”
strategy [72]. Numerous studies focus on the increment
of beta frequency power (13–35 Hz) in PD and tremor
[73–75]. Little et al. [3, 76, 77] designed an on-demand
adaptive DBS that digitally filters the biomarker around
the beta frequency (22 Hz), generating a smoothed beta
amplitude. Then, they utilize it as an input to the con-
troller that regularly checks the beta oscillatory ampli-
tude with respect to a personalized threshold (different
in each patient). Instead of providing an on–off strategy,
Rosa et al. [78] presented an algorithm that continuously
and linearly modifies the stimulation parameters each
second according to the changes in the patient’s LFP
beta power (13–17 Hz).
One of the concerns about the use of the beta fre-
quency band as a feedback biomarker is that it might be
affected and suppressed by movement [79]. This issue is
not an important problem in the experimental studies
Fig. 3 The process of real-time closed-loop DBS programming. The recording unit records the biomarker signal via an inserted electrode inside (I)
or outside (II) of the brain based on the biomarker type. After signal conditioning (amplification and filtration), the biomarker signal is digitized
and then sent to the controller unit. Then, through a computational model (A), the biomarker signal is evaluated from different aspects (e.g.
amplitude, frequency, and pulse-width, etc.) to define the response signal, which is then employed to predict optimized stimulation parameters.
The bottom model (B) has been adopted from [105] and then modified. It represents the structure of controller where X (t), Y (t), and Z (t) are the
input vector, neural circuit states, and biomarker response, respectively. The mapping functions from input to the neural state and from neural
state to the biomarker response are demonstrated by f (X,t) and g (X,Y,t), respectively. The k (Z,t) is the controller that evaluates the biomarker
response and updates stimulation parameters. The estimated parameters are adjusted in the stimulation unit to create the stimulation pulses for
applying to the stimulation electrodes. In this real-time process, a very short time-window of the recorded signal is used for prediction of the
stimulation parameters. The time-window of biomarker signal is pushed forward continuously and simultaneous computations are done to
predict and update the next stimulation-window
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when the patient is motionless. However, in a beta-based
closed-loop DBS device implanted in the patient’s brain,
the patient’s movements can supress the beta amplitude
which may degrade the closed-loop performance.
Another concern relates to the accuracy of the promis-
ing outcomes of beta-based studies due to the fact that
they only test the patients in a temporary time period
(after electrode implantation and before surgery to
implant the pulse generator, when the leads are access-
ible). This period, known as post-operative “stun effect”,
is believed to causes unrealistic outcomes as a result of
temporary alleviation of PD symptoms even without
stimulation [80, 81]. However, a recent published paper
[82] presents a proof of principle to the chronic applica-
tion of adaptive DBS, and confirms the accuracy of the
closed-loop DBS in the temporary period. Piña-Fuentes
et al. [82] presented the first case of closed-loop DBS in
a PD patient with chronic STN-DBS treatment, and
concluded that closed-loop DBS can be applied in the
chronically implanted DBS phase, and is at least as ef-
fective as open-loop DBS when objectively assessed [82].
Beyond the “amplitude-responsive” strategy for control-
ling the stimulation pulses in a closed-loop DBS, there is
another strategy termed “phase-responsive”. In a phase re-
sponsive closed loop DBS, the stimulations are directed by
the phase (timing) of the biomarker signal [72]. The phase-
responsive closed-loop DBS is currently being developed
for treatment of tremor, aiming to selectively stimulate at
the phases that attenuate the tremor amplitude through an
accelerometer attached to the tremulous hand [72, 83]. The
results of this control strategy show a significant tremor
relief in essential tremor patients [83]. Thus far, the phase-
responsive closed-loop DBS has not been applied for longer
than 30 s [72].
Technological advancements towards closed-loop
DBS devices
In this section, the existing closed-loop DBS systems both
from hardware (circuit design) and software (control
algorithm and programming) perspectives are reviewed.
Stimulation artifact suppression
The stimulation current pulses can cause interference
with reading of biomarkers of interest. This interference
makes it difficult to accurately record and process
biomarkers because of the large difference in the ampli-
tude of the stimulation pulses and the measured signal.
For instance, the magnitude of LFPs is roughly five to
six fold (100–120 dB) smaller than that of the stimula-
tion pulses [84]. This difference yields a combination of
strong stimulation artifact (in volts range) with a weak
neural signal (in μV range), which saturates the ampli-
fiers used in the recorder.
To alleviate this problem, Rossi et al. [84] designed
“FilterDBS” which is an artifact-free recording system for
acquisition of LFPs from the DBS lead positioned in the
STN. The 130 Hz stimulation artifact and the higher
harmonics were separated in the frequency domain
using a bandpass filter (2–40 Hz). This system benefits
from an overall gain of 100 dB with 130 dB common
mode rejection ratio (CMRR). However, the device
requires a ± 15 V supply to operate. Post-filtering is
another method to remove the stimulation artifact [85],
in which the template of the stimulation signal is
subtracted from the recorded signal to produce an
artifact-free biomarker. However, this method degrades
the signal quality which is not desirable. Moreover, it
may not operate correctly in the closed-loop DBS where
the stimulation rate fluctuates.
Stanslaski et al. [86] designed an implantable,
chronic, adaptive DBS device that benefits from an
LFP/ECoG sensor. This device was validated success-
fully in an ovine model of epilepsy. The hippocampus
seizure activity was detected and measured during
and after stimulation. The separation of the bio-
marker from the stimulation artifact was conducted
through a support vector machine classification
algorithm by processing of the spectral fluctuations.
The suggested device fits in a 39cm3 space, employing
front-end filtering that guarantees the op-amp input
to be within its normal operation area [86]. In
another work, Zbrzeski et al. [87] introduced an
integrated neural amplifier to reduce artifacts in the
recording of LFPs and spikes. The proposed neural
amplifier occupies a space of 0.15 mm2 and consumes
6.73 μW of power. Test-bench validation of the amp-
lifier showed a mid-band gain of 20 dB with a low
input-referred noise of 4 μVrms. However, despite the
advances in the simultaneous recording and stimula-
tion, the issue of stimulation artifact in the recorded
signal has not been fully addressed yet in the existing
DBS systems.
Stimulation challenges
A. Stimulation pattern
The pattern of stimulation is a major concern for both
open-loop and closed-loop DBS devices. Figure 4 shows
the differences between monophasic (a fully positive
(cathodic) or a fully negative (anodic) pulse) versus
biphasic (a pulse having both anodic and cathodic sides)
stimulations. Whilst monophasic pulses are charge-
imbalanced, biphasic pulses can be charge-imbalanced
or charge-balanced. Being imbalanced in terms of charge
yields formation of undesirable chemical reactions at the
electrode contact surface over time [88]. Therefore,
monophasic and charge-imbalanced biphasic pulses can
be dangerous for the brain tissue due to their non-zero
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net charge that can create a lesion. Charge-balanced
pulses can be obtained through passive or active charge
balancing schemes. In the active methods, the second
pulse is truly built using a second current source or
through a further complex circuitry with one current
source. However, in the passive charge-balancing
scheme, a passive components or shortening of the elec-
trodes to the ground is used. Although charge-balanced
biphasic pulses may prevent net charge injection into
the stimulated tissue [88], the anodic phase neutralizes
the anticipated stimulation effect of the cathodic phase
[89]. Typically, an inter-pulse interval is applied to the
biphasic pulses in order to avoid cells hyperpolarization
and minimize the suppressing and altering effects of the
anodic phase [89]. It is worth stating that most of the
available market-based open-loop and closed-loop DBS
systems use a passive charge-balancing scheme.
Ewing et al. proposed a DBS device named SaBer DBS
[90]. It delivers biphasic, passive charge-balanced pulses
to two independent channels. Immediately after deliver-
ing the stimulation pulses, the electrodes are grounded
(capacitive coupling) to achieve the zero-net charge.
Although it is programmable in frequency, pulse-width,
and current amplitude, the user defines the stimulation
parameters; thus, the system is not closed-loop.
Moreover, lack of inter-pulse interval between the cath-
odic and anodic pulses may alter neuronal activities.
Sooksood et al. [89] proposed a novel active approach
for charge balancing via long-term offset regulation.
Using this method, the voltage of the electrode is
checked after each stimulation pulse to fall within a
predefined range. If not, the mismatch is compensated
via an adjusted offset current. The power-efficient DBS
system designed by Lee et al. [91] uses the offset regula-
tion method. They designed a power-efficient DBS
system that employs closed-loop active charge balancing
scheme (by utilizing a small balancing current pulse) to
retain the charge within a safe window (50 mV). It is
also capable of estimating the residual time remained for
balancing.
Apart from the pattern shape, a temporally irregular
(i.e. variable inter-burst interval) stimulation pattern in
the closed-loop DBS has caused concerns regarding the
effectiveness of stimulation. On one hand, it has been
observed that irregular stimulation patterns can reduce
the beneficial therapeutic effects [92, 93]. On the other
hand, the closed-loop DBS appears to be irregular
because of the adaptive variations. Rosin et al. [2]
applied both closed-loop stimulation and random stimu-
lation (unrelated to the ongoing activity) patterns in two
PD monkeys. They observed that in spite of the irregular
pattern of the closed-loop DBS, it is a successful thera-
peutic method. It was explained that the adaptive (symp-
tom-related) nature of the closed-loop DBS induces the
therapeutic effects regardless of its pattern’s irregularity.
B. Stimulation type
Delivering method of stimulation pulses, whether to
dispatch constant-current-controlled (CC) or constant-
voltage-controlled (CV) stimulation, is a matter of debate.
Most of the available commercial DBS devices offer the CV
stimulators due to their higher level of power efficiency
[14]. In the CC stimulation, the dropout voltage across the
current source wastes the power and reduces the device
battery life. On the other hand, the current and the volume
of the tissue activated in CV devices may alter because of
the impedance variations in the brain tissue and the
electrode-tissue interface [94]. Whereas the CC stimulators
provide a more precise control independent of the imped-
ance variations. Impedance fluctuations have been observed
Fig. 4 Categorization of different stimulation patterns. For additional details regarding the pros and cons of each waveform refer to [89, 162]
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during the first 3 months following DBS surgery [95, 96] as
well as post-implantation [26, 97, 98]. Satzer et al. [99]
highlight a mean 73 Ω/year reduction in impedance in
most electrode contacts; thus, utilizing CC devices is more
preferred. However, in terms of effectiveness, there is no
proven evidence to give CC preference over CV stimulation
[100]. Although better clinical outcomes were reported via
CC stimulation in patients suffering from dystonia in the
Lettieri et al. experiment [94], the study had some limita-
tions as discussed in ref. [101].
In order to improve the power efficiency problem in CC
stimulators, Azin et al. [102] proposed a closed-loop DBS
device which controls the stimulator supply voltage
adaptively through an inductive link. It is a 4-channel intra-
cortical micro-stimulation integrated circuit (IC) (10.9 mm2
system on chip (SoC)) that converts recorded extracellular
neural spikes to electrical stimulations for real-time deliver-
ing from one brain region to another [102]. It comprises a
voltage readout channel to close the feedback loop.
Moreover, it includes a direct current (DC) to DC converter
that converts a single 1.5 V battery to 5.05 V to supply the
micro-stimulating back-end circuit. Similarly, Hyung-Min
et al. [91] designed a 4-channel wireless CC stimulator with
a closed-loop supply control that utilizes a voltage readout
channel. The voltage readout channel automatically con-
trols the stimulation voltage and improves the efficiency
(30% higher than a fixed supply voltage). This prototype
has been verified in vitro, occupies 2.25 mm2 with 5 V peak
alternating current (AC) input (rectified to a DC voltage
between 2.5 V to 4.6 V) at 2 MHz.
Portable closed-loop DBS
Another issue is the size and weight of the closed-
loop DBS device. Compared to the open-loop DBS
devices, closed-loop systems have additional recording
and programming circuits which increase the size and
weight of the final design. Because the initial experi-
ments are usually carried out in small laboratory ani-
mals, it is necessary that the device be miniature and
lightweight, allowing stimulation during the animal
life cycle (eating, playing, walking, sleeping, etc.). The
issue is even more important when the device is
expected to be used for long-term experiments.
Providing a balance of functionality, portability, the
number of input and output channels, and power
requirements in the closed-loop DBS devices demand
a comprehensive research.
Jongwoo et al. [103] developed a 64-channel
programmable IC to be used as closed-loop DBS device for
treatment of neurological disorders. This device employs
eight low-noise front-end pre-amplifiers, single 200 kS/s
8-bit logarithmic pipeline analog to digital converter
(ADC), and digital filters. It has been implemented in
0.18 μm complementary metal–oxide–semiconductor
(CMOS) technology and benefits from 2.7 mm2 occupied
space. Both LFPs and spikes are sensed and then separated
through on-chip digital filters. The proposed device
consumes 89 μW in a normal mode and 271 μW in a con-
figuration mode from 1.8 V supply. In addition, Pinnell et
al. [104] developed a miniature wireless closed-loop CC
DBS with a total weight of 8.5 g to be used with laboratory
animal. This system operates for more than 8 h and trans-
mits LFPs to 3–5 m distances. Another recent effort to-
wards the portability is the work done by Arlotti et al. [16].
They have developed an external portable closed-loop DBS
for clinical experiments in freely-moving PD patients. This
device analyses LFPs recorded from a single differential
artifact-free channel. The external part weights 150 g occu-
pying 12 × 7 × 2.5 cm3 in space. It can be worn externally
by humans to investigate closed-loop DBS effectiveness.
However, it is a large and heavy device for small laboratory
animals.
Battery-less closed-loop DBS
Another hurdle in designing a closed-loop DBS is the possi-
bility of continuous biomarker recording and real-time pro-
cessing with least energy consumption. Some researchers
have developed DBS devices that consume low power
[105–107]. However, these devices have limitations with
lack of re-chargeability and limited memory space. These
weaknesses can impose potential surgery risks and extra
costs on patients [108].
The invention of energy harvesting technology has in-
creased the battery lifetime of DBS devices, reducing the
frequency of surgical replacement procedures, and subse-
quently minimizing the extra costs. Harvesting the power
from human or environmental sources (kinetic, electromag-
netic, thermal and infrared radiant energies) have been
discussed in a review by Hannan et al. [109]. The review sug-
gests the inductive coupling link as a more suitable method
of powering the battery-less implantable biomedical devices.
Harrison et al. [42] designed a neural recording system in
which power and command are transferred wirelessly (at
6.5 kb/s) via a 2.64 MHz inductive link. In other studies,
Hosain et al. [110–112] proposed a four-layer circular planar
inverted-F antenna to harvest power for adaptive DBS im-
plants and examined the feasibility of wireless transmission
of power, control, and command signals. They then proposed
RF rectifiers for electromagnetic power harvesting in a DBS
implant [113]. Besides these, a system-on-chip wireless
closed-loop DBS was developed by Hyo-Gyuem et al. [25,
114] which is capable of two-way wireless telemetry through
RF energy harvesting. Lin et al. [115] proposed another
battery-less, implantable neuro-electronic interface capable
of two-way wireless telemetry. It receives power through a
single coil and transmits data via the same coil. The device
has been fabricated with the standard 0.18 μm CMOS
technology with a chip area of 7.74 mm.
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Patient-friendly closed-loop DBS monitoring
Another demand is providing a more patient-friendly
closed-loop DBS device by making commands through
wireless data communications for home care facilities. Early
detection of DBS side effects could result in immediate
action of neurologists in modifying stimulation parameters.
This cannot be achieved unless through a long-term and
ongoing monitoring of the disease state. Even in the closed-
loop DBS where programming is done automatically, the
need for monitoring the stimulator related side-effects
exists [116]. Apart from the stimulator’s side effects, the
battery capacity needs to be monitored after implantation
to avoid hazards of battery depletion [116].
Upon development of information technology, telemedi-
cine is progressively applied for various medical applica-
tions. However, only a few programs have focused on
connecting DBS devices to the hospital networks. A web--
based platform (WebBioBank) for neurophysiological DBS
data collection has been developed for integration of PD
clinical data [117, 118]. This system creates a reference
guideline for home care and monitoring of DBS patients. It
is capable of connecting to patient’s smartphone and safely
share the information to improve the care quality for DBS
patients. However, such an integrated system is in the early
stages of development and requires further research to be-
come available not only to PD patients but also to other
treatable disorders via DBS. In another study, Chen et al.
[119] first identified the DBS telemedicine requirements
through a questionnaire responded by 22 patients and 9
neurosurgeons. The results indicated that providing of an
urgent remote adjustment was needed. Moreover, the pre-
ferred communication method was the video telehealth
interaction. According to their findings, adding an inter-
action mode to the DBS systems was proposed. Then, they
successfully tested the functionality of the idea on three
patients.
Commercial closed-loop DBS devices
DBS devices have been in commercial use since 1997 when
the food and drug administration (FDA) organization
approved the utilization of neurostimulator devices for
tremor treatment [120]. Since then, they have been also
approved for other disorders such as PD in 2002 [121],
dystonia in 2003 [122] and obsessive-compulsive disorder
(OCD) in 2009 [123]. The Activa system by Medtronic
(Minneapolis, MN, USA) is a widespread open-loop DBS
device. However, other companies such as Boston Scientific
and St. Jude Medical also manufactured comparable
products.
The study of the relevant literature shows that there is
currently only one commercially available brain stimulation
system that provides closed-loop DBS (The closed-loop
RNS system by NeuroPace for closed-loop cortical stimula-
tion). The closed-loop RNS system can stimulate depth
and/or cortical tissues of the brain using two different types
of leads. It is a responsive battery powered closed-loop DBS
capable of continuous sensing of ECoG potentials. The
RNS system has received FDA approval to be used as an
alternative option for treatment of drug-resistant epilepsy
patients [124]. Upon recognition of a predefined pattern
relating to seizure in the recorded signal, the stimulator is
activated to remove the pattern. This device stores
segments of ECoG potentials. In addition, it can be
programmed to store information about the detected elec-
trographic events (e.g. the date and time of seizure
occurrence).
Another commercial closed-loop DBS system is the
Activa PC + S which is an implantable sensing-stimulating
DBS device manufactured by Medtronic. This device has
been designed for investigational purposes. The PC + S
system can provide concurrent LFP sensing and stimula-
tion. However, it does not use the sensed information for
adjusting the stimulation pulses [125], unless the user
compiles a program into the device and closes the feed-
back loop. If Medtronic provides an upgrade for the PC + S
system with all the necessary programs for closing the
feedback loop, then, the Activa PC + S system can func-
tion as a complete closed-loop DBS device.
Discussions
Weakness of open-loop DBS devices
Once a conventional DBS system is implanted, the
stimulation parameters need to be defined. The proced-
ure in which the optimum stimulation parameters are
defined per each subject is a trial-and-error-based
programming task that is carried out by clinicians. Using
a set of guidelines, the stimulation parameters are chan-
ged based on the observable behavioral responses to the
previous stimulation parameters [126]. Unfortunately,
this procedure is a subject-dependent and time-
consuming task that may frustrates both the clinician
and patient.
Although the neurologists reprogram the open-loop DBS
to enhance the therapeutic results, this reprogramming is
not an optimal method. Even by achieving an optimum set
of parameters in one effort, there is no guarantee that the
symptom relief response will last long due to the brain
neural plasticity. Neural plasticity usually occurs after
prolonged DBS resulting in reduced efficacy over time. For
instance, Ricchi et al. [127] observed that the gait improve-
ment obtained by switching the stimulation frequency from
130 Hz to 80 Hz was not achievable at follow-up sessions.
Occasionally, it is feasible to recapture the efficacy of open-
loop DBS using a coordinated reset (CR) stimulation [128,
129], which is a short-duration stimulation interval for re-
wiring of neuronal networks [130]. Many computational
studies reported optimization of CR stimulation so that long
lasting therapeutic effects can be achieved [64, 65, 131]. The
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results were obtained in rat hippocampal slices [132],
MPTP-treated monkeys [133, 134], human PD patients
[135] as well as in tinnitus patients [136, 137]. The out-
comes confirm the robustness of CR open-loop stimulation
for the treatment of neurological disorders characterized by
abnormal neuronal synchronization [131]. Note, the appli-
cation of CR stimulation is not limited to open-loop DBS,
and can also be used with closed-loop DBS in a demand-
controlled manner [128, 129, 138] to fight against induced
neural plasticity over time.
Furthermore, the open-loop programming procedure
may not be practicable for all kind of neural disor-
ders. For instance, the therapeutic response to the
programming of stimulation parameters could take
several weeks to finalize for depression or dystonia
[71, 139], while being instantly evident for epilepsy,
tremor, and PD [71]. Taking a longer time for appear-
ance of the therapeutic response makes it hard for
neurologists to decide whether the adjusted parame-
ters are superior to the previous settings or not.
Therefore, the open-loop programming could be inef-
ficient for certain neurological disorders.
Another weakness of open-loop DBS devices is that its
frequent programming sessions incur additional costs to
the patients. Patients normally don’t like the numerous
clinic visits required for adjustments of parameters to
optimize their symptom relief response. In addition, repro-
gramming of open-loop DBS devices needs regular involve-
ment of clinical experts. Therefore, this could be an extra
burden on clinics to employ and instruct clinical staffs to
train them skills in open-loop DBS programming [140].
In addition, open-loop DBS devices are faced with the
issues associated with battery life due to their continu-
ous and non-stop stimulation pulses. One issue is that
battery replacement requires a surgery which imposes
potential risks (e.g. surgery risks, anesthesia risks) to the
patient [3].
In summary, open-loop DBS therapy has several weak-
nesses including: (1) subject dependency, (2) time-
consuming programming, (3) lack of dynamical adjustment
of stimulation parameters, (4) frequent visits to clinic for
programming, (5) extra costs in visits to clinic, (6) ineffi-
ciency for some neurological disorders (e.g. disorders with
a lag response to the stimulation), (7) regular involvement
of programming experts, and (8) short battery life in
battery-operated devices. Hence, the open-loop program-
ming of DBS devices is not optimal method and might not
result in the best therapeutic effects.
Comparison of closed-loop DBS devices
A comparison of the existing closed-loop DBS devices is
presented in Table 2. It provides an evaluation of the
existing device from different technical standpoints.
Although these devices have common functional
features, they incorporate different monitoring and
stimulation designs, control methods, and internal
features. Some of these devices close the feedback loop
by turning the stimulation on and off known as on-
demand stimulation [31, 32, 104, 141]. The stimulation
is delivered only when the abnormal phase of biomarker
is detected. While other devices take a step forward and
update at least one stimulation parameter based on the
biomarker state, usually pulse amplitude [86, 102, 114].
The existing closed-loop DBS devices (as compared in
Table 2) employ only one biomarker in the control unit
to decide on the adjustment of stimulation parameters.
While some of the devices can be used to record more
than one biomarker (e.g. LFPs and APs), but they cannot
detect and process multiple biomarkers concurrently.
Therefore, only one biomarker is used as a feedback to
control the DBS pulse generator. Using only one bio-
marker to close the feedback loop has the disadvantage
of being affected by noise and artifacts. Occasionally,
due to the device internal or external environmental
conditions, the biomarker and the electrodes can be af-
fected by some unexpected noises and artifacts. These
unexpected conditions include, but not limited to, mag-
netic field interactions, induced electric currents,
temperature variations, device functional disruptions
[142, 143]. If the device is affected by one of the stated
conditions, the biomarker will be affected and a wrong
decision will be made by the controller. Consequently,
the DBS unit will adjust the stimulation parameters un-
related to the variations in the patient clinical state.
Being unrelated to the disease may lead to either oppos-
ing pathological effects or insufficient treatment.
Moreover, the neurons may get damaged because of the
incorrect adjustment of the stimulation parameters
[144]. One solution is to provide the controller with
multiple feedback signals [145]. Whenever a fault occurs
in one biomarker sensing path, there will be another
path to steer the closed-loop operation. Therefore, this
could increase the robustness of the closed-loop DBS
device and decrease the chance of inaccurate adjustment
of stimulation parameters.
Issues with closed-loop DBS devices
While closed-loop DBS has shown superiority in improve-
ment of clinical outcomes [2], it faces several issues (sum-
marized in Fig. 5). One of the challenges is finding a
reliable biomarker linked to the patient’s symptoms.
Although several physiological and biochemical bio-
markers have been introduced for closing the feedback
loop, some of the biomarkers such as LFPs, AP, ECoG,
and EEG are affected by the stimulation pulses. Thus, the
detection of the biomarker is affected requiring sophisti-
cated artifact removing circuitry to improve the detection
of the biomarker. Thus far, several artifact rejection
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techniques have been developed to tackle the impact of
stimulation on biomarker recording [84, 86, 87, 146];
however, the issue has been resolved partially in the
current closed-loop DBS devices.
Another challenge is related to the type of stimulation.
The clinical difference between CC and CV stimulation
needs to be investigated to find out which approach is
more advantageous. The pattern of stimulation is another
concern due to the fact that a charge-imbalanced pulse
would cause damages to the brain tissue. Most of the
available market-based open-loop and closed-loop DBS
systems use a passive charge-balancing scheme, requiring
further investigation and upgrade to an active charge-
balancing scheme in order to avoid the weaknesses of the
passive charge-balancing as described by Sooksood et al.
[89]. On one hand, because of safety issues, the pattern of
stimulation pulses needs to be biphasic. On the other
hand, biphasic pulses can alter neural activities and lead to
suppressing effects on the action potentials. As a conse-
quence, more studies need to explore the clinical impact
of charge-balanced and charge-imbalanced stimulation
pulses in the closed-loop DBS devices. In addition, the
role of stimulation patterns will need to be investigated to
be able to answer the remaining questions on the mecha-
nisms and benefits of DBS.
In order to evaluate the effectiveness of the closed-
loop DBS devices or examine new applications, the de-
vices need to be validated in-vivo. Due to the small size
of most of laboratory animals and also because of the
need for long-term experiments, the devices need to
have compact size and light-weight, be portable and im-
plantable, and have a tetherless (wireless) configuration
to not disturb animal freedom of movement. These are
considered as other challenges in designing a closed-
loop DBS device. Since closed-loop DBS devices have
recording circuitry, the total size and weight of the de-
vice may be affected.
In addition, in terms of power consumption, closed-
loop DBS devices are expected to consume less power
compared with their open-loop counterparts. The reason
is that closed-loop devices deliver electrical stimulation
based on the state of the brain. Therefore, these devices
remain less active over a course of time which results in a
reduction of the electrical energy delivered to the brain
[4]. However, closed-loop devices have extra recording
and processing circuits that could increase the overall
power consumption of the device. Therefore, the potential
power saving of these devices would depend on the use of
low-power recording and analysis circuits.
Although closed-loop DBS devices have a control algo-
rithm that automatically modifies the stimulation parame-
ters according to the patient’s brain state, they may still
require regular assessments of the stimulator related side-
effects and, if necessary, reprogramming of the control
algorithm for minimization of adverse-effects. Developing
an optimal control algorithm and/or discovering an
Fig. 5 Closed-loop DBS research challenges. These challenges are classifiable in three major parts including monitoring issues (blue part),
stimulation challenges (yellow part), and design expectation concerns (red part)
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optimum biomarker individualized to each patient can
take a long time. Therefore, the patients are required to
pay extra costs associated with the service. Designing a
patient-friendly closed-loop DBS device is another re-
quirement that deserves consideration. This means that
providing wireless data and command communications
for home care applications is needed to reduce costs and
improve care quality.
There are also other concerns associated with the
closed-loop DBS therapy, one of them being the effect of
pharmacological approaches on the nature and magnitude
of measured biomarkers of interest. Simultaneous medica-
tion (either oral or injection) with DBS therapy could
affect the neuronal activities and change the amplitude of
the recorded biomarker. As an example, it has been
observed that beta activity is suppressed with levodopa
treatment in PD patients [80]. In addition, it has been also
demonstrated that DBS could suppress beta activity in
off-medication state [147]. However, the patterns of beta
oscillations following DBS, differ from those after medica-
tion [148]. Simultaneous pharmacological intervention
could potentially attempt to change the closed-loop DBS
results when applied. Besides the pharmacological inter-
vention, the interaction of progressive severity of the
disease may affect the measured biomarkers. Very little
work has been done to demonstrate a correlation between
a particular biomarker and disease severity over time. In
the presence of an opposite correlation, this factor might
pose a problem for the use of biomarker in the feedback
loop. Therefore, it reinforces the use of individualized bio-
markers based on patient’s clinical phenotype or use of
combination of biomarkers [48].
Another concern is alleviation of a range of disease
symptoms using a single biomarker (or multiple bio-
markers). Take PD for instance, each patient may experi-
ence different primary (e.g. tremor, bradykinesia, rigidity,
postural instability, etc.) or secondary (e.g. freezing,
micrographia, mask-like expression, unwanted accelera-
tions) motor symptoms [149]. Some of these symptoms
are promoted by different pathophysiological neuronal
networks and, therefore, may require different bio-
markers to detect. Thus, amelioration of a range of PD
motor symptoms through least a number of biomarkers
need further and future investigations. Viability of bio-
marker recordings over the course of several years is an-
other concern. The choice of sensing methodology,
electrode materials and components in the implants,
could potentially increase the viability of biomarker re-
cordings. The use of LFPs, which could be recorded
from the same lead used to induce DBS, also offers a
more stable biomarker measurements. However, selec-
tion of a biomarker that requires a separate recording
path from those implanted for DBS may not assure the
viability of recordings and require further investigations.
Towards commercializing closed-loop DBS devices
The promising clinical effects of open-loop DBS have been
demonstrated, indicating DBS as a pioneer technology
and treatment option to serve neurological patients.
Moreover, the significant increase in the number of com-
mercial open-loop DBS devices represents the approach
effectiveness. However, like other commercial devices,
DBS needs to be automated and modernized. Currently,
in the open-loop DBS approach, the stimulation parame-
ters are periodically adjusted by neurologists and the
parameters remain constant in the intervals of two subse-
quent visits regardless of any variations in the patient’s
clinical state. Therefore, it may cause brain overstimula-
tion or produce fewer benefits because of insufficient
stimulations. Closed-loop DBS can eliminate brain over-
stimulation and provide maximum stimulation efficiency
for those in need of DBS therapy.
Despite the advancements in the closed-loop DBS de-
vices, most current commercial DBS systems operate in
an open-loop manner. To date, only one commercial
closed-loop DBS device has been manufactured (the RNS
system). However, life expectancy of IPGs is not very good
for the RNS system. The battery charge is rapidly depleted
when stimulation is used heavily, and the control
algorithm is currently conventional based on on-demand
(On-Off) approach [125]. A closed-loop DBS device re-
quires an adaptive algorithm to learn and optimize the
stimulation parameters according to the brain clinical
state. Owing to the fact that each patient is different, such
an algorithm may need to be patient dependent.
Conclusion
Recent advances in the closed-loop DBS systems provide a
brighter future for patients in need of DBS treatment. The
next generation of DBS devices is expected to be fully and
automatically programmable, compatible with biomarker
variations, and flexible in stimulation type and pattern, to
yield greater benefits and fewer side effects. Since a new
technology has to be accessible to all patients over the
world, the next closed-loop designs need to be inexpensive
to become available even in developing countries. In
addition, it can be expected that the device operates based
on multiple biomarkers to decrease the chance of malfunc-
tion and guarantee the robustness of the closed-loop DBS
operation. Engineers need to provide a balance and trade-
off among the device features by considering the clinical
effectiveness, and the technological costs of the device.
However, whether the future advancements in the closed-
loop DBS devices can result in a better life and efficient care
for their users need to be yet demonstrated. Alongside all
the advancements and benefits that closed-loop DBS de-
vices can bring to the patients, other brain stimulation
methods e.g. optogenetics and ultrasonic stimulations are
also receiving attention by research communities.
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